{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:48:22Z","timestamp":1783129702366,"version":"3.54.6"},"reference-count":53,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.064","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T17:03:58Z","timestamp":1651251838000},"page":"3330-3337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["TAK\u00a0\u2212\u00a0021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice"],"prefix":"10.1016","volume":"40","author":[{"given":"Kanami","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Kohnoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takashino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyousuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovkesh","family":"Karwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fue","family":"Vang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi J.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2022.04.064_b0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1473-3099(10)70194-8","article-title":"Virology, epidemiology, pathogenesis, and control of enterovirus 71","volume":"10","author":"Solomon","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.064_b0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/1471-2334-13-539","article-title":"Epidemiology and clinical characteristics of hand foot, and mouth disease in a Shenzhen sentinel hospital from 2009 to 2011","volume":"13","author":"Wang","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.064_b0015","unstructured":"WHO. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). 2011."},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.064_b0020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(13)70342-6","article-title":"Hand, foot, and mouth disease in China, 2008\u201312: an epidemiological study","volume":"14","author":"Xing","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.064_b0025","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJM199909233411302","article-title":"Neurologic complications in children with enterovirus 71 infection","volume":"341","author":"Huang","year":"1999","journal-title":"New England J Med"},{"issue":"9125","key":"10.1016\/j.vaccine.2022.04.064_b0030","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(98)24031-1","article-title":"Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease","volume":"352","author":"Lin","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.064_b0035","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/infdis\/129.3.304","article-title":"An apparently new enterovirus isolated from patients with disease of the central nervous system","volume":"129","author":"Schmidt","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.064_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-019-0573-2","article-title":"The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region","volume":"26","author":"Puenpa","year":"2019","journal-title":"J Biomed Sci"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.064_b0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7883\/yoken.63.422","article-title":"Changing epidemiology of hand, foot, and mouth disease in Hong Kong, 2001\u20132009","volume":"63","author":"Ma","year":"2010","journal-title":"Jpn J Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.064_b0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJM199909233411301","article-title":"An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group","volume":"341","author":"Ho","year":"1999","journal-title":"New England J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.064_b0055","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1128\/JCM.43.12.6171-6175.2005","article-title":"Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003","volume":"43","author":"Mizuta","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.064_b0060","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1086\/314032","article-title":"Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group","volume":"31","author":"Chan","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.064_b0065","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3201\/eid1812.120929","article-title":"Enterovirus 71-associated hand, foot, and mouth disease, Southern Vietnam, 2011","volume":"18","author":"Khanh","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.064_b0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3201\/eid2201.151323","article-title":"Seroepidemiology of Human Enterovirus 71 Infection among Children","volume":"22","author":"Horwood","year":"2016","journal-title":"Cambodia Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.064_b0075","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1128\/JCM.40.8.2823-2827.2002","article-title":"Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers","volume":"40","author":"Singh","year":"2002","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.064_b0080","doi-asserted-by":"crossref","first-page":"e1737","DOI":"10.1371\/journal.pntd.0001737","article-title":"Challenges to licensure of enterovirus 71 vaccines","volume":"6","author":"Lee","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.064_b0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/cid\/ciu852","article-title":"Review of enterovirus 71 vaccines","volume":"60","author":"Chong","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.064_b0090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1023\/A:1024071514438","article-title":"Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells","volume":"25","author":"Hu","year":"2003","journal-title":"Biotechnol Lett"},{"issue":"44","key":"10.1016\/j.vaccine.2022.04.064_b0095","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1016\/j.vaccine.2015.05.108","article-title":"Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates","volume":"33","author":"Lim","year":"2015","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.064_b0100","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.vaccine.2013.05.019","article-title":"Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2022.04.064_b0105","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.vaccine.2015.03.034","article-title":"High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice","volume":"33","author":"Zhang","year":"2015","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.064_b0110","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.vaccine.2008.01.058","article-title":"Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge","volume":"26","author":"Chung","year":"2008","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.vaccine.2022.04.064_b0115","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.vaccine.2015.08.016","article-title":"Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71","volume":"33","author":"Zhang","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.064_b0120","doi-asserted-by":"crossref","first-page":"e0003692","DOI":"10.1371\/journal.pntd.0003692","article-title":"Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease","volume":"9","author":"Tsou","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2022.04.064_b0125","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1016\/j.vaccine.2016.06.058","article-title":"Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges","volume":"34","author":"Yan","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.064_b0130","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.micinf.2006.01.021","article-title":"Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71","volume":"8","author":"Chiu","year":"2006","journal-title":"Microbes and infection \/ Institut Pasteur"},{"issue":"5-6","key":"10.1016\/j.vaccine.2022.04.064_b0135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0264-410X(01)00385-1","article-title":"Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus","volume":"20","author":"Wu","year":"2001","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2022.04.064_b0140","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1016\/j.vaccine.2015.10.103","article-title":"Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection","volume":"33","author":"Kim","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.064_b0145","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jmv.24018","article-title":"Characterization of the enterovirus 71 VP1 protein as a vaccine candidate","volume":"87","author":"Zhou","year":"2015","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2022.04.064_b0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-0556-5-6","article-title":"DNA vaccine constructs against enterovirus 71 elicit immune response in mice","volume":"5","author":"Tung","year":"2007","journal-title":"Genetic Vaccines Therapy"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.064_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02308-18","article-title":"Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate","volume":"93","author":"Tsai","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.04.064_b0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12929-019-0560-7","article-title":"Antivirals and vaccines for Enterovirus A71","volume":"26","author":"Lin","year":"2019","journal-title":"J Biomed Sci"},{"issue":"9882","key":"10.1016\/j.vaccine.2022.04.064_b0165","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.064_b0170","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"New England J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.064_b0175","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"New England J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.04.064_b0180","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.vaccine.2013.03.015","article-title":"A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine","volume":"31","author":"Cheng","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.064_b0185","doi-asserted-by":"crossref","first-page":"e2538","DOI":"10.1371\/journal.pntd.0002538","article-title":"Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine","volume":"7","author":"Hwa","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2022.04.064_b0190","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1016\/j.vaccine.2019.06.023","article-title":"An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages","volume":"37","author":"Tambyah","year":"2019","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.064_b0195","doi-asserted-by":"crossref","first-page":"e106756","DOI":"10.1371\/journal.pone.0106756","article-title":"Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.064_b0200","doi-asserted-by":"crossref","first-page":"e79783","DOI":"10.1371\/journal.pone.0079783","article-title":"Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers","volume":"8","author":"Chou","year":"2013","journal-title":"PLoS ONE"},{"issue":"24","key":"10.1016\/j.vaccine.2022.04.064_b0205","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.vaccine.2009.03.060","article-title":"Cross-antigenicity among EV71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007","volume":"27","author":"Mizuta","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.064_b0210","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01921-19","article-title":"Development of an Enterovirus 71 Vaccine Efficacy Test Using Human Scavenger Receptor B2 Transgenic Mice","volume":"94","author":"Imura","year":"2020","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.064_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00682-18","article-title":"VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection","volume":"92","author":"Fujii","year":"2018","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.064_b0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1423-0127-21-31","article-title":"Animal models of enterovirus 71 infection: applications and limitations","volume":"21","author":"Wang","year":"2014","journal-title":"J Biomed Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.064_b0225","doi-asserted-by":"crossref","first-page":"e59501","DOI":"10.1371\/journal.pone.0059501","article-title":"Adaptation of enterovirus 71 to adult interferon deficient mice","volume":"8","author":"Caine","year":"2013","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.064_b0230","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nm.1992","article-title":"Scavenger receptor B2 is a cellular receptor for enterovirus 71","volume":"15","author":"Yamayoshi","year":"2009","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.064_b0235","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1128\/JVI.00020-12","article-title":"Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71","volume":"86","author":"Yamayoshi","year":"2012","journal-title":"J Virol"},{"issue":"36","key":"10.1016\/j.vaccine.2022.04.064_b0240","doi-asserted-by":"crossref","first-page":"14753","DOI":"10.1073\/pnas.1217563110","article-title":"Transgenic mouse model for the study of enterovirus 71 neuropathogenesis","volume":"110","author":"Fujii","year":"2013","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.064_b0245","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1080\/22221751.2021.1934558","article-title":"A practical method for evaluating the in vivo efficacy of EVA-71 vaccine using a hSCARB2 knock-in mouse model","volume":"10","author":"Wu","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.064_b0250","doi-asserted-by":"crossref","first-page":"e57591","DOI":"10.1371\/journal.pone.0057591","article-title":"Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.064_b0255","doi-asserted-by":"crossref","first-page":"e1008428","DOI":"10.1371\/journal.ppat.1008428","article-title":"Heparan sulfate attachment receptor is a major selection factor for attenuated enterovirus 71 mutants during cell culture adaptation","volume":"16","author":"Kobayashi","year":"2020","journal-title":"PLoS Pathog"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.064_b0260","doi-asserted-by":"crossref","first-page":"e2067","DOI":"10.1371\/journal.pntd.0002067","article-title":"Cross-reactive neutralizing antibody responses to enterovirus 71 infections in young children: implications for vaccine development","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.064_b0265","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0448-7","article-title":"Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations","volume":"13","author":"Liu","year":"2015","journal-title":"BMC Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:12Z","timestamp":1759403652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":53,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22005187"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAK\u00a0\u2212\u00a0021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}